10-Q: Forte Biosciences Reports Q3 2024 Results, Faces Liquidity Concerns

Forte Biosciences reports a net loss of $28.3 million for the first nine months of 2024 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Summary

• Forte Biosciences, a clinical-stage biopharmaceutical company, released its financial results for the third quarter of 2024.
• The company reported a net loss of $8.39 million for the three months ended September 30, 2024, and a net loss of $28.32 million for the nine months ended September 30, 2024.
• Research and development expenses were $5.87 million for the quarter and $15.96 million for the nine-month period.
• General and administrative expenses were $2.76 million for the quarter and $13.29 million for the nine-month period.
• As of September 30, 2024, Forte had cash and cash equivalents of $16.36 million.
• The company has an accumulated deficit of $146.8 million and used $20.7 million of cash in operating activities during the nine months ended September 30, 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern without additional funding.
• Forte is currently advancing its lead product candidate, FB102, into patient-based trials, with top-line results expected in the second quarter of 2025.

Sentiment

Score: 3

Explanation: The document expresses significant concerns about the company's financial viability and ability to continue as a going concern, which overshadows the positive aspects of its clinical development progress. The need for additional funding and the risks associated with a single product candidate contribute to a negative sentiment.

Positives

• The Phase 1 healthy volunteer trial for FB102 was successfully completed.
• A patient-based trial for FB102 in celiac disease was initiated in the third quarter of 2024.
• Top-line results from the celiac disease trial are expected in the second quarter of 2025.
• FB102 has shown significant reductions in the NK cell pharmacodynamic marker in studies.
• The company has a patent for administering a combination of bacteria for skin conditions, although this is not material to the FB102 program.

Negatives

• The company has incurred significant losses since its inception and expects to continue to incur losses.
• Forte has an accumulated deficit of $146.8 million.
• The company's cash and cash equivalents are insufficient to fund operations for the next twelve months.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is dependent on the success of FB102, which is still in clinical development.
• The company has a limited operating history and no approved products.
• The company is subject to risks associated with pharmaceutical development, including clinical trial failures and regulatory hurdles.
• The company is restricted in its ability to access additional funding from the sale of securities under Form S-3.

Risks

• Forte's current liquidity position and recurring losses raise substantial doubt about its ability to continue as a going concern.
• The company will require additional capital to fund its operations and may not be able to obtain necessary financing.
• Forte's business is almost entirely dependent on the success of developing FB102, which may not be successful.
• Results from early preclinical studies and clinical trials may not be predictive of results from later stage studies or clinical trials.
• Forte has no approved products and has a limited operating history, which may make it difficult to evaluate its technology and product development capabilities and predict its future performance.
• Clinical development is a lengthy and expensive process, with an uncertain outcome.
• The market opportunities for FB102 may be limited and Forte's estimates of the incidence and prevalence of its target patient populations may be inaccurate.
• If Forte is unable to obtain and maintain patent protection for any product candidate Forte develops, its competitors could develop and commercialize similar products.
• Forte expects to rely on third parties to conduct its preclinical studies and clinical trials and to manufacture its product candidates.
• The market price of Forte's common stock is expected to be volatile.
• Forte previously identified a material weakness in its internal control over financial reporting.
• A variety of risks associated with public health threats and epidemics, including any resurgence of the COVID-19 pandemic, could materially adversely affect Forte's business.

Future Outlook

Management expects to continue to incur additional losses in the foreseeable future as the Company continues its development efforts on advancing FB102 through clinical trials and expects top-line results from the celiac disease trial in the second quarter of 2025. The company also expects to finance its operations through a combination of public or private equity or debt financings or other capital sources.

Management Comments

• Management expects to continue to incur additional losses in the foreseeable future as the Company continues its development efforts on advancing FB102 through clinical trials.
• Given these factors, the Company has concluded that the existing cash and cash equivalents will not be sufficient for the twelve months following the financial statement issuance date, and requires additional liquidity to continue its operations.

Industry Context

The company operates in the competitive biopharmaceutical industry, focusing on autoimmune and autoimmune-related diseases. The development of FB102 is aimed at addressing key pathways implicated in these indications. The company faces competition from major pharmaceutical and biotechnology companies, as well as academic institutions and research organizations.

Comparison to Industry Standards

• Forte's financial situation is not uncommon for clinical-stage biopharmaceutical companies, which often operate at a loss while developing their product candidates.
• The company's cash burn rate and accumulated deficit are typical for companies in this stage of development, but the explicit statement of doubt about its ability to continue as a going concern is a significant concern.
• Compared to other companies in the sector, Forte's reliance on a single product candidate, FB102, makes it particularly vulnerable to setbacks in clinical development.
• Many companies in the sector have multiple product candidates in their pipelines to mitigate the risk of failure of a single program.
• The company's research and development expenses are in line with other companies at a similar stage, but the high general and administrative expenses may be a concern.
• The company's need for additional funding is a common challenge for clinical-stage biopharmaceutical companies, but the explicit statement of doubt about its ability to continue as a going concern is a significant concern.

Legal Proceedings

• A stockholder lawsuit, Camac Fund, LP v. Paul A. Wagner, et al., was settled, with the company paying $1.5 million in legal fees.
• A lawsuit filed by the company against Camac Fund, LP, et al., was dismissed with prejudice.
• The company filed a complaint against its insurance carriers, Wesco Insurance Co., et al., for refusing to provide coverage for legal proceedings.

Related Party Transactions

• One of the company's board of directors received cash payments of $150 thousand and $329 thousand for scientific consulting services during the three and nine months ended September 30, 2024.
• Certain executive officers, senior management, and board members of the Company participated in the Private Placement, purchasing approximately $1.16 million of shares of common stock.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and need for additional funding.
• Employees may be concerned about the company's ability to continue operations and their job security.
• Customers (potential patients) may be concerned about the company's ability to bring FB102 to market.
• Suppliers and creditors face increased risk of non-payment due to the company's financial situation.

Next Steps

• The company will continue to advance FB102 into patient-based trials.
• The company expects top-line results from the celiac disease trial in the second quarter of 2025.
• The company will seek additional funding through various means.
• The company will continue to monitor the potential impacts of global events on its business.

Key Dates

Keywords

FB102, biopharmaceutical, clinical trials, autoimmune, monoclonal antibody, research and development, financial results, liquidity, going concern, celiac disease